• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Guidelines for Switching From Methadone to Buprenorphine

Guidelines for Switching From Methadone to Buprenorphine

May 1, 2018
Rehan Aziz, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Rehan Aziz, MD. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Lintzeris N et al, J Addict Med 2018. doi:10.1097/ADM.0000000000000396

Recent guidelines published by the American Society of Addiction Medicine and nationally in Australia provide support for transferring patients from methadone to buprenorphine-naloxone (BNX). Patients may switch, thinking BNX is easier to discontinue or because of methadone side effects. The transition can be complicated by relapses or precipitated withdrawal when starting BNX. To minimize adverse events, the Australian guidelines recommend the following:

  1. Consider inpatient treatment for patients with significant medical comorbidities, unstable social conditions, or for those transferring from high methadone doses (> 50 mg/day)

  2. Gradually reduce methadone until the patient experiences mild to moderate opioid withdrawal symptoms between doses

  3. Stop methadone and begin monitoring regularly for opioid withdrawal, using measures such as the Clinical Opioid Withdrawal Scale (COWS)

  4. Start low-dose BNX at 2 mg, at least 24 hours after the last dose of methadone and after the patient experiences moderate opioid withdrawal (COWS score > 12), monitoring hourly afterwards for precipitated withdrawal

  5. Administer 6 mg after 1 hour; additional doses, 4–8 mg, are symptom-triggered

  6. On successive days: BNX dosage = the previous day’s dose plus additional symptom-triggered doses


Lintzeris and colleagues studied the clinical feasibility of these guidelines. Involving 4 Australian specialist addiction centers, they conducted a prospective cohort study. They reviewed medical records. Outcomes assessed included guideline feasibility, transfer practices, and patient responses.

In all, 33 adult participants transferred, 9 from low-dose (LD) methadone (< 30 mg/day), 9 from medium-dose (MD) methadone (30–50 mg/day), and 15 from high-dose (HD) methadone (> 50 mg/day). Most HD transfers occurred in inpatient settings (93%), while most MD/LD transfers occurred in outpatient settings (67%). Inpatient stays were 2.2 days on average. Seventy percent of transfers were consistent with the guidelines. Most patients stabilized their BNX dose by day 3, with 96% using ≥ 12 mg/day. Overall, 79% (26/33) were still on BNX treatment at day 7 and were considered to have successfully transferred.

Three patients experienced precipitated withdrawal, all in the HD group, all returning to methadone. Three patients resumed methadone due to anxiety and poor sleep with BNX. One participant relapsed and used heroin for several days before resuming methadone.

CATR’s Take
Although this was a small sample, the findings are useful. They suggest most patients can successfully transfer from methadone to BNX when using the guidelines. Those transferring from HD methadone require inpatient settings and specialist supervision, while two-thirds of MD/LD methadone transfers may be suitable for outpatient clinics. Since all those patients failed transfer, it is important to avoid precipitated withdrawal.
Addiction Treatment
KEYWORDS addiction psychopharmacology_tips research-update
Rehan Aziz, MD.

Mood Stabilizers for Bipolar Disorder in Older Adults: Special Considerations

More from this author
www.thecarlatreport.com
Issue Date: May 1, 2018
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Pain and Addiction, CATR May/June 2018
Treating Chronic Pain When There’s Addiction: A Primer
Assessing and Treating Psychogenic Pain
Using Caution While Prescribing Opioids for Pain
Prevalence of Fetal Alcohol Spectrum Disorder
Is Varenicline Effective for Alcohol Use Disorder?
Guidelines for Switching From Methadone to Buprenorphine
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.